{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=27",
    "query": {
      "intervention": "Control II",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 2665,
    "total_pages": 267,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T04:44:41.238Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04398199",
      "title": "Study of Hypofractionated Radiotherapy Alone in Locally Advanced Nonsmall Cell Lung Cancer Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonsmall Cell Lung Cancer, Stage II",
        "Nonsmall Cell Lung Cancer Stage III"
      ],
      "interventions": [
        {
          "name": "Hypofractionated Radiation Therapy",
          "type": "DRUG"
        },
        {
          "name": "Radiation Boost",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2020-10-16",
      "completion_date": "2020-11-20",
      "has_results": true,
      "last_update_posted_date": "2022-10-05",
      "last_synced_at": "2026-10-24T04:44:41.238Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04398199"
    },
    {
      "nct_id": "NCT00880399",
      "title": "A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "orvepitant",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 328,
      "start_date": "2009-03-01",
      "completion_date": "2010-06-16",
      "has_results": true,
      "last_update_posted_date": "2017-09-12",
      "last_synced_at": "2026-10-24T04:44:41.238Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Arcadia, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00880399"
    },
    {
      "nct_id": "NCT03190967",
      "title": "T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Brain Metastasis",
        "Brain Cancer"
      ],
      "interventions": [
        {
          "name": "T-DM1",
          "type": "DRUG"
        },
        {
          "name": "TMZ",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2018-04-18",
      "completion_date": "2023-06-13",
      "has_results": true,
      "last_update_posted_date": "2023-10-11",
      "last_synced_at": "2026-10-24T04:44:41.238Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03190967"
    },
    {
      "nct_id": "NCT00113009",
      "title": "Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peripheral Vascular Disease"
      ],
      "interventions": [
        {
          "name": "VLTS-934",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Valentis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "78 Years",
        "sex": "ALL",
        "summary": "40 Years to 78 Years"
      },
      "enrollment_count": 148,
      "start_date": "2005-03",
      "completion_date": "2006-07",
      "has_results": false,
      "last_update_posted_date": "2007-11-22",
      "last_synced_at": "2026-10-24T04:44:41.238Z",
      "location_count": 32,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00113009"
    },
    {
      "nct_id": "NCT00063076",
      "title": "Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Alopecia Areata"
      ],
      "interventions": [
        {
          "name": "Targretin Gel 1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2003-05",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2012-08-02",
      "last_synced_at": "2026-10-24T04:44:41.238Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00063076"
    },
    {
      "nct_id": "NCT02633397",
      "title": "A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Riociguat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mark Gladwin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2017-04-11",
      "completion_date": "2022-05-04",
      "has_results": true,
      "last_update_posted_date": "2023-07-19",
      "last_synced_at": "2026-10-24T04:44:41.238Z",
      "location_count": 20,
      "location_summary": "Oakland, California • Washington D.C., District of Columbia • Miami, Florida + 17 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02633397"
    },
    {
      "nct_id": "NCT00602160",
      "title": "Therapeutic Effect of Chinese Herbal Medicine on Food Allergy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Food Allergy"
      ],
      "interventions": [
        {
          "name": "FAHF-2 (TM)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Li, Xiu-Min, M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "12 Years to 45 Years"
      },
      "enrollment_count": 68,
      "start_date": "2007-12",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2010-11-04",
      "last_synced_at": "2026-10-24T04:44:41.238Z",
      "location_count": 2,
      "location_summary": "Little Rock, Arkansas • New York, New York",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00602160"
    },
    {
      "nct_id": "NCT00027703",
      "title": "Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Mesothelioma",
        "Epithelial Mesothelioma",
        "Localized Malignant Mesothelioma",
        "Recurrent Malignant Mesothelioma",
        "Sarcomatous Mesothelioma"
      ],
      "interventions": [
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2001-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-02-11",
      "last_synced_at": "2026-10-24T04:44:41.238Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00027703"
    },
    {
      "nct_id": "NCT01894555",
      "title": "Pharmacogenomics of Antiplatelet Response - II (PARes-II)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atherothrombosis"
      ],
      "interventions": [
        {
          "name": "Aspirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "45 Years to 75 Years"
      },
      "enrollment_count": 33,
      "start_date": "2013-01",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2017-01-09",
      "last_synced_at": "2026-10-24T04:44:41.238Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01894555"
    },
    {
      "nct_id": "NCT01892579",
      "title": "Reducing Agitation in People With Dementia: the Customized Activity Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dementia"
      ],
      "interventions": [
        {
          "name": "Tailored Activity Program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Home Safety and Education Program",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2013-11",
      "completion_date": "2017-11-23",
      "has_results": false,
      "last_update_posted_date": "2019-09-23",
      "last_synced_at": "2026-10-24T04:44:41.238Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01892579"
    }
  ]
}